ATAIBECKLEY INC (ATAI)

What ATAIBECKLEY INC does

AtaiBeckley is a clinical-stage biotechnology company developing novel therapeutics, with a focus on product candidates targeting neuropsychiatric and psychiatric conditions, including those derived from controlled substances research. The company is in the preclinical and clinical development phases for multiple product candidates and has not yet commercialized any approved therapies. As a research-driven biotech enterprise, AtaiBeckley relies on external funding and third-party clinical trial sites to advance its pipeline toward regulatory approval.

Fundamentals

• Price$5.33 as of 2026-07-09 close
• Market cap$2.0B as of 2026-07-10
• 1-year return+100.4% as of 2026-07-09 close
• Net margin-19019.4% as of 2026-07-10
• ROE-366.5% as of 2026-07-10
• Debt / equity0.00 as of 2026-07-10
• Revenue growth (YoY)+86.7% as of 2026-07-10
• Beta1.62 as of 2026-07-10

Ask why ATAI looks like this →

Key risks (from latest filing)

["Clinical-stage development with uncertain outcomes: all product candidates are in preclinical or clinical development, with no guarantee of regulatory approval or successful commercialization","Significant ongoing losses and funding dependency: the company is unprofitable with substantial operating losses and depends on external capital raises, which risk dilution and operational constraints if funding becomes unavailable","Regulatory and jurisdictional challenges: the use of controlled substances in product candidates may restrict commercialization in certain jurisdictions and create legal uncertainty around production and sale"]

See ATAI's biggest risks from its latest 10-Q →

Competitors & peers

• Compass Pathways
• Usona Institute
• MAPS (Multidisciplinary Association for Psychedelic Studies)
• Eleusis (now Perception Neuroscience)
• Beckley Foundation
• Tryp Therapeutics
• Janssen Pharmaceuticals (JNJ)

Not quite? Describe exactly what you want →